BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31659412)

  • 1. Cardiovascular Incidence in 6900 Patients with Differentiated Thyroid Cancer: a Swedish Nationwide Study.
    Zoltek M; Andersson TM; Hedman C; Ihre-Lundgren C; Nordenvall C
    World J Surg; 2020 Feb; 44(2):436-441. PubMed ID: 31659412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Risk of Atrial Fibrillation After Treatment for Differentiated Thyroid Carcinoma.
    Klein Hesselink EN; Lefrandt JD; Schuurmans EP; Burgerhof JG; Groen B; Gansevoort RT; van der Horst-Schrivers AN; Dullaart RP; Van Gelder IC; Brouwers AH; Rienstra M; Links TP
    J Clin Endocrinol Metab; 2015 Dec; 100(12):4563-9. PubMed ID: 26480284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of incident circulatory disease in patients treated for differentiated thyroid carcinoma with no history of cardiovascular disease.
    Toulis KA; Viola D; Gkoutos G; Keerthy D; Boelaert K; Nirantharakumar K
    Clin Endocrinol (Oxf); 2019 Aug; 91(2):323-330. PubMed ID: 30993728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between thyroid cancer and cardiovascular disease risk: a nationwide observation study.
    Tsai MC; Hsieh CT; Hsu HY; Yeh TL; Lee WC; Chiang CJ; Hsiao BY; Jhuang JR; Tsai WH; Cheng SP; Chou CL; Lee CC; Liu SC; Tseng PJ; Chien KL
    Sci Rep; 2022 Nov; 12(1):18438. PubMed ID: 36323730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Adverse Cardiovascular Outcomes in Differentiated Thyroid Cancer Survivors: A Systematic Review and Meta-Analysis.
    Qiang JK; Alwithenani R; Uleryk E; Ezzat S; Lipscombe LL; Sawka AM
    Thyroid; 2023 Feb; 33(2):192-202. PubMed ID: 36074932
    [No Abstract]   [Full Text] [Related]  

  • 6. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.
    Biondi B; Cooper DS
    Thyroid; 2010 Feb; 20(2):135-46. PubMed ID: 20151821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma.
    Wang LY; Smith AW; Palmer FL; Tuttle RM; Mahrous A; Nixon IJ; Patel SG; Ganly I; Fagin JA; Boucai L
    Thyroid; 2015 Mar; 25(3):300-7. PubMed ID: 25386760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study.
    Klein Hesselink EN; Klein Hesselink MS; de Bock GH; Gansevoort RT; Bakker SJ; Vredeveld EJ; van der Horst-Schrivers AN; van der Horst IC; Kamphuisen PW; Plukker JT; Links TP; Lefrandt JD
    J Clin Oncol; 2013 Nov; 31(32):4046-53. PubMed ID: 24101052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is the incidence of differentiated thyroid cancer increased in patients with thyrotropin-secreting adenomas? Report of three cases from a large consecutive series.
    Perticone F; Pigliaru F; Mariotti S; Deiana L; Furlani L; Mortini P; Losa M
    Thyroid; 2015 Apr; 25(4):417-24. PubMed ID: 25647054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burden, timing, and relationship of cardiovascular hospitalization to mortality among Medicare beneficiaries with newly diagnosed atrial fibrillation.
    Turakhia MP; Solomon MD; Jhaveri M; Davis P; Eber MR; Conrad R; Summers N; Lakdawalla D
    Am Heart J; 2013 Sep; 166(3):573-80. PubMed ID: 24016509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incident atrial fibrillation in patients with differentiated thyroid cancer: a meta-analysis.
    Kostopoulos G; Doundoulakis I; Antza C; Bouras E; Nirantharakumar K; Tsiachris D; Thomas GN; Lip GYH; Toulis KA
    Endocr Relat Cancer; 2021 Apr; 28(5):325-335. PubMed ID: 33794503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NT-proBNP is increased in differentiated thyroid carcinoma patients and may predict cardiovascular risk.
    Klein Hesselink EN; van der Horst-Schrivers ANA; van der Horst ICC; Bakker SJL; Muller Kobold AC; Brouwers AH; de Bock GH; Gietema JA; Dullaart RPF; Links TP; Lefrandt JD
    Clin Biochem; 2017 Aug; 50(12):696-702. PubMed ID: 28242284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Thyroid-Related Symptoms on Long-Term Quality of Life in Patients with Differentiated Thyroid Carcinoma: A Population-Based Study in Sweden.
    Hedman C; Djärv T; Strang P; Lundgren CI
    Thyroid; 2017 Aug; 27(8):1034-1042. PubMed ID: 28474541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of second primary malignancy on outcomes of differentiated thyroid carcinoma.
    Lang BH; Lo CY; Wong IO; Cowling BJ
    Surgery; 2010 Dec; 148(6):1191-6; discussion 1196-7. PubMed ID: 21134551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular Outcomes in Thyroid Cancer Patients Treated With Thyroidectomy: A Meta-analysis.
    Lee EK; Ahn HY; Ku EJ; Yoo WS; Lee YK; Nam KH; Chai YJ; Moon S; Jung YS
    J Clin Endocrinol Metab; 2021 Nov; 106(12):3644-3654. PubMed ID: 34347085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral arterial disease and atrial fibrillation and risk of stroke, heart failure hospitalization and cardiovascular death: A nationwide cohort study.
    Lin YS; Tung TH; Wang J; Chen YF; Chen TH; Lin MS; Chi CC; Chen MC
    Int J Cardiol; 2016 Jan; 203():204-11. PubMed ID: 26512838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Italian cancer figures, report 2013: Multiple tumours.
    AIRTUM Working Group
    Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
    Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
    Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body Composition, Resting Energy Expenditure, and Metabolic Changes in Women Diagnosed with Differentiated Thyroid Carcinoma.
    Izkhakov E; Vaisman N; Barnes S; Barchana M; Stern N; Keinan-Boker L
    Thyroid; 2019 Aug; 29(8):1044-1051. PubMed ID: 31088334
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer.
    Do Cao C; Wémeau JL
    Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S47-52. PubMed ID: 26826483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.